Stay updated on Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The record now presents details of the completed Phase 2 study of ipilimumab and nivolumab for advanced non-small cell lung cancer resistant to anti-PD-1-axis therapy. It also includes eligibility criteria, study outcomes, investigator and date information, and the study protocol and statistical analysis plan.
    Difference
    50%
    Check dated 2026-11-09T13:58:46.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision identifier was updated from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-02T16:12:51.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T16:00:36.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer’s site revision label changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-19T20:46:28.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label updated from v3.7.0 to v3.7.1 while the page remained a 403 error page.
    Difference
    0.2%
    Check dated 2026-10-13T03:51:10.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study record content. This indicates access is blocked to this entry.
    Difference
    19%
    Check dated 2026-09-21T22:53:11.000Z thumbnail image

Stay in the know with updates to Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.